CCLD.NASDAQCarecloud, INC

10-Q: CareCloud Reports Q1 2025 Results, Revenue Up 6% and Resumes Preferred Stock Dividends

Sentiment:

Quarterly Report


CareCloud, Inc. announces a 6% increase in net revenue for Q1 2025 and the resumption of preferred stock dividends, alongside strategic cost management efforts.

Delay expectedThe Board of Directors suspended the monthly cash dividends for Series A Preferred Stock and Series B Preferred Stock beginning with the payment scheduled for December 15, 2023 together with the remaining dividends that were declared.As a result of such suspension, as of the filing date of this Quarterly Report, the Company has approximately $7.3 million of dividends in arrears.
Capital raiseThe company filed a Form S-3 with the SEC in April 2025 to allow it to sell various securities in the public market.The Form S-3 became effective on April 24, 2025.
Better than expectedThe company reported a net income of $1.9 million, a significant turnaround from a net loss of $241,000 in Q1 2024.Net revenue increased by 6% to $27.6 million in Q1 2025.Preferred stock dividends were resumed in February 2025 after being suspended in December 2023.

Summary

  • CareCloud, Inc. reported its financial results for the quarter ended March 31, 2025.
  • Net revenue increased by 6% to $27.6 million compared to $26.0 million in Q1 2024.
  • The company achieved net income of $1.9 million, a significant improvement from the $241,000 net loss in the same period last year.
  • The company resumed payment of preferred stock dividends in February 2025.
  • The company's offshore operations in Pakistan and Sri Lanka accounted for approximately 17% of total expenses for the three months ended March 31, 2025.
  • The company's cash position increased to $6.8 million as of March 31, 2025, compared to $5.1 million at the end of 2024.
  • The company filed a Form S-3 with the SEC in April 2025 to allow it to sell various securities in the public market.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company shows improved financial performance with increased revenue and a return to profitability. The resumption of preferred stock dividends is also a positive sign. However, the existing dividend arrears and potential risks related to the banking system and market competition temper the overall outlook.

Positives

  • Net revenue increased by 6% year-over-year.
  • The company achieved net income, a significant improvement from the previous year's net loss.
  • Resumption of preferred stock dividends may be viewed favorably by investors.
  • The company's cash position improved.
  • The company is actively integrating AI into its products.
  • The company is focused on cost management and profitability improvements.
  • The company completed an acquisition of an audiology-focused revenue cycle management company in April 2025.

Negatives

  • The company has approximately $7.3 million of dividends in arrears.
  • The company maintains cash balances at Silicon Valley Bank (SVB), a division of First Citizens Bank & Trust Company in excess of the FDIC insurance coverage limits.
  • The company has incurred cumulative losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax losses difficult to support in accordance with ASC 740.

Risks

  • The company's ability to manage growth, including integrating acquired businesses, is a risk.
  • Maintaining client retention and revenue levels is crucial for sustained performance.
  • The company's offshore operations are subject to political and economic risks.
  • Keeping pace with the rapidly changing healthcare industry is a continuous challenge.
  • Compliance with various regulations and maintaining data privacy are ongoing concerns.
  • The company's ability to attract and retain key personnel is critical.
  • The company's ability to comply with covenants contained in its credit agreement with its senior secured lender, Silicon Valley Bank, a division of First Citizens Bank, and other future debt facilities is a risk.
  • The company's ability to incorporate AI into its products faster and more successfully than its competitors, protecting the privacy of medical records and cybersecurity threats is a risk.
  • The company's ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have is a risk.
  • The company's ability to effectively integrate, manage and keep our information systems secure and operational in the event of a cyber-attack is a risk.
  • The company's ability to respond to the uncertainty resulting from pandemics, epidemics or other public health emergencies and the impact they may have on our operations, the demand for our services, our projected results of operations, financial performance or other financial metrics or any of the foregoing risks and economic activity in general is a risk.
  • The company's ability to keep and increase market acceptance of our products and services is a risk.
  • Changes in domestic and foreign business, market, financial, political and legal conditions is a risk.

Future Outlook

Management expects that efforts to manage expenses and grow revenue will continue to enhance the company's liquidity and financial position, and forecasts sufficient liquidity to meet obligations for the next twelve months.

Management Comments

  • Management continues to focus on the Company's overall profitability, including managing expenses, and to the extent possible growing revenue, and expects that these efforts will continue to enhance our liquidity and financial position.

Industry Context

CareCloud operates in the healthcare information technology sector, providing revenue cycle management and cloud-based solutions. The industry is characterized by increasing regulatory complexity, the need for efficient practice management, and the growing adoption of digital health solutions. CareCloud's focus on technology-enabled services and AI aligns with these trends.

Comparison to Industry Standards

  • CareCloud competes with companies like athenahealth, Cerner (now Oracle Health), and Allscripts in the healthcare IT space.
  • athenahealth, for example, also offers cloud-based EHR and revenue cycle management solutions.
  • CareCloud's focus on offshore operations for cost efficiency is a strategy employed by some other players in the industry to maintain competitive pricing.
  • The company's move to incorporate AI into its offerings mirrors a broader trend in the industry to leverage AI for clinical decision support and workflow automation.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Amendment to Certificate of DesignationsAmended certain provisions of the 11 % Series A Cumulative Redeemable Preferred Stock, including reducing the dividend rate to 8.75 % per annum.2024-09-11Reduced monthly dividend payments and provided change of control protections to Series A Preferred Stock holders.

Legal Proceedings

  • The company was involved in several legal proceedings, including a settlement with Ramapo Anesthesiologists, PC, a settlement with a former customer in New Jersey State Court, a settlement related to transition costs from a prior acquisition, and a settlement with a former customer in Massachusetts State Court.

Related Party Transactions

  • The company had sales to a related party, a physician who is the wife of the Executive Chairman.
  • The company leases its corporate office and other facilities from the Executive Chairman.
  • The company entered into a consulting agreement with an entity owned and controlled by a member of its Board of Directors.

Stakeholder Impact

  • Shareholders may be positively impacted by the resumption of preferred stock dividends and improved financial performance.
  • Employees may be affected by restructuring activities and workforce realignments.
  • Customers may benefit from the company's focus on technology-enabled solutions and AI integration.
  • The company's financial stability and growth prospects could impact suppliers and creditors.

Next Steps

  • Continue to manage expenses and grow revenue to enhance liquidity and financial position.
  • Monitor the financial health of bank relationships.
  • Integrate the acquired audiology-focused revenue cycle management company.
  • Execute the potential sale of securities under the Form S-3.

Key Dates

DateDescription
2023-12-11Board of Directors suspended monthly cash dividends for Series A and Series B Preferred Stock.
2024-09-11Certificate of Amendment to the Certificate of Designations, Preferences and Rights of 11 % Series A Cumulative Redeemable Preferred Stock became effective.
2025-01Common stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million.
2025-02Company resumed monthly payment of dividends on the Series A and B Preferred Stock.
2025-03-06Board of Directors elected to exercise its conversion rights, which provided for the conversion of each share of Series A Preferred Stock into 7.3358 shares of common stock, inclusive of all accumulated and unpaid dividends.
2025-03-31End of the quarterly period.
2025-04Company completed an acquisition of an audiology-focused revenue cycle management company.
2025-04Company filed a Form S-3 with the SEC to allow it to sell various securities in the public market.
2025-04-24The Form S-3 became effective.
2025-05-06Date of report.

Keywords

revenue cycle management, healthcare IT, SaaS, preferred stock, dividends, financial results, CareCloud, AI, acquisition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.